Semi-Synthetic Artemisinin - The Beginning of the SynthBio Revolution? - An Interview with Jay Keasling

Hosted By: Gerald Clarke
Rate this Podcast: 
Be the first!
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

About this Podcast...

Artemisinin is a front line anti-malarial drug which was derived from the sweet wormwood plant. ‘Growing on trees’ however, isn’t all it’s cracked up to be and the supply could be unpredictable.  Professor Jay Keasling, using synthetic biology techniques, had grown his own artemisinin in the lab and with support from the Bill and Melinda Gates Foundation and Sanofi, the industrial-scale “brewing” of artemisinin now promises to be the first successful application of this amazing technology in pharma. Pharma IQ spoke to Professor Keasling about this project and the potential future applications of synthetic biology in pharma.


The Hilton Del Mar hotel, San Diego, CA, United States
February 19 - 20, 2018
The Westin Grand Munich, Munich, Germany
February 18 - 21, 2018
United States
February 25 - 27, 2018